Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

AI blood test could spot heart attacks faster

NCT ID NCT06384846

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing whether artificial intelligence (AI) can predict or rule out a heart attack using data from standard blood tests. Researchers will analyze white blood cell properties from over 3,000 adults who come to the hospital with chest pain. The goal is to see if AI can match or improve upon current heart attack blood tests, potentially leading to quicker and more accurate diagnosis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to faster, more accurate diagnosis of heart attacks using standard blood tests, potentially saving lives by speeding up treatment.
What could go wrong
This is an observational study, not a treatment trial. The AI models are still being developed and tested, so they may not perform better than current methods. Results may not apply to all populations or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 3,350 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients recruited at LKH-Universitätsklinikum Graz / Medical University of Graz, including subjects presenting to the emergency department or facilities of the Department of Cardiology, including the cardiac catheter laboratory and outpatient facilities. The study population includes adults with suspected acute coronary syndrome as well as subjects with no or stable angina pectoris depending on cohort assignment.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: General inclusion criteria: * Male or female, aged 18 years or above. * Participant is willing and able to give informed consent for participation in the study. * Collection of WBC and hs-cTn data must be possible. * Criteria for timing of blood sampling for collection of WBC and hs-cTn data must be fulfilled, where applicable. Case cohort: * Suspicion of STEMI or NSTE-ACS according to current ESC guidelines. * Coronary angiography must have been performed within 72 hours after initial suspicion of ACS. * For patients qualifying for observation according to ESC guidelines, coronary angiography is not mandatory and time limits do not apply. * Confirmation of STEMI or NSTE-ACS by identification of a culprit lesion using coronary angiography; identical evaluation results by review board required. * For observation patients without coronary angiography, final discharge diagnosis is used to decide about the presence or absence of NSTEMI and/or ACS. * Criteria for timing of blood sampling for collection of WBC and hs-cTn data must be fulfilled. Control cohort: * Suspicion of STEMI or NSTE-ACS according to current ESC guidelines. * Coronary angiography must have been performed within 72 hours after initial suspicion of ACS. * No identification of a culprit lesion compatible with diagnosis of STEMI or NSTE-ACS during coronary angiography; identical evaluation results by review board required. * Criteria for timing of blood sampling for collection of WBC and hs-cTn data must be fulfilled. Supplementary cohort: * Subject presents without chest pain or with stable angina pectoris. * No indication for revascularization during coronary angiography; identical evaluation results by review board required. * Exclusion of elevated hs-cTn. * Criteria for timing of blood sampling for collection of WBC and hs-cTn data must be fulfilled. * Between initial blood sampling to collect WBC data and coronary angiography, the subject must not develop suspicion of ACS. Rule-out cohort: * Suspicion of NSTE-ACS and NSTEMI rule-out according to current ESC guidelines, i.e. very low initial hs-cTn value, or low initial hs-cTn value and no significant 1-hour/2-hour change in hs-cTn value. * No coronary angiography within 72 hours. * Criteria for timing of blood sampling for collection of WBC and hs-cTn data must be fulfilled. All-comer cohort: * Subject presents to the emergency department with suspected ACS. * Clinical assessments, ECG, and measurements of hs-cTn, single or serial measurement, must be conducted according to ESC guidelines. * Collection of WBC data must be performed at initial blood withdrawal after admission to the emergency department. * Review board evaluations must confirm the presence or absence of a culprit lesion if coronary angiography was performed, as outlined for the case and control cohorts. Exclusion Criteria: * Age below 18 years. * Subject refuses informed consent. * Collection of WBC and hs-cTn data is not possible. * Criteria for timing of blood sampling for collection of WBC and hs-cTn data cannot be fulfilled. * Suspicion of ACS occurs in subjects with no or stable angina pectoris any time between initial blood sampling and start of coronary angiography.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute coronary syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Landeskrankenhaus-Universitätsklinikum Graz

    RECRUITING

    Graz, Styria / Steiermark, 8036, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.